// App-Quantinova.ai

: Bronchoalveolar Lavage Pentraxin 3 Levels during Clinically-Stable Minimal Acute Rejection are Associated with CLAD and Death Risk

Researchers

Presenter

  • L. Levy

Principal Investigators

  • E. Huszti

  • R. Ghany

  • M. Ahmed

  • S. Hunter

  • K. Zhang

  • K. Boonstra

  • W. Klement

  • S. Moshkelgosha

  • J. Tikkanen

  • L. Singer

  • S. Keshavjee

  • S. Juvet

  • T. Martinu

Medical Centers

  • Toronto Lung Transplant Program, UHN, Toronto, ON, Canada

  • Biostatistics Research Unit, University Health Network, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Transplant rejection

Biomarkers

  • Pentraxin-3

  • Albumin/creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved